De-escalating cancer treatments during COVID 19 pandemic: Is metronomic chemotherapy a reasonable option?

Graphical abstract

• Publication year

  2020

• Venue

  Critical reviews in oncology/hematology

• Publication date

  2020-11-18

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.critrevonc.2020.103148PMID 33254036PMCID 7672334
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The official French guidelines to protect patients with cancer against SARS-CoV-2 infection

  2020cited by this paper
• Active and Effective Measures for the Care of Patients With Cancer During the COVID-19 Spread in China.

  2020influential reference
• Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective

  2020cited by this paper
• Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China

  2020cited by this paper
• A study of capecitabine metronomic chemotherapy is non-inferior to conventional chemotherapy as maintenance strategy in responders after induction therapy in metastatic colorectal cancer

  2020cited by this paper
• Phase I/II Study of Palliative Triple Metronomic Chemotherapy in Platinum-Refractory/Early-Failure Oral Cancer.

  2019cited by this paper
• Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial.

  2019cited by this paper
• Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer.

  2019cited by this paper
• Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells

  2019cited by this paper
• The NAME trial: a direct comparison of classical oral Navelbine versus metronomic Navelbine in metastatic breast cancer.

  2019cited by this paper
• Metronomic chemotherapy with cyclophosphamide plus low dose of corticosteroids in advanced castration-resistant prostate cancer across the era of taxanes and new hormonal drugs

  2019cited by this paper
• Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis

  2019cited by this paper
• An individual patient-data meta-analysis of metronomic oral vinorelbine in metastatic non-small cell lung cancer

  2019cited by this paper
• Metronomic Chemotherapy for First-Line Treatment of Metastatic Triple-Negative Breast Cancer: A Phase II Trial

  2018cited by this paper
• Metronomic Chemotherapy with Vinorelbine Produces Clinical Benefit and Low Toxicity in Frail Elderly Patients Affected by Advanced Non-Small Cell Lung Cancer

  2018cited by this paper
• Oral Metronomic Vinorelbine (OMV) in elderly or pretreated patients with advanced non small cell lung cancer: outcome and pharmacokinetics in the real world

  2018cited by this paper
• Metronomic therapy in metastatic castrate-resistant prostate cancer: Experience from a tertiary cancer care center.

  2018cited by this paper
• Regulatory T cells: a potential target in cancer immunotherapy

  2018cited by this paper
• P2.03a-032 Palliative Chemotherapy with Oral Metronomic Vinorelbine in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unsuitable for Chemotherapy: Topic: Clinical Trials

  2017cited by this paper
• Current achievements and future perspectives of metronomic chemotherapy

  2017cited by this paper
• Radiotherapy prolongs the survival of advanced non-small-cell lung cancer patients undergone to an immune-modulating treatment with dose-fractioned cisplatin and metronomic etoposide and bevacizumab (mPEBev)

  2017cited by this paper
• Efficacy of metronomic vinorelbine in elderly patients with advanced non-small-cell lung cancer and poor performance status.

  2017cited by this paper
• Continuous oral cyclophosphamide as salvage or maintenance therapy in ovarian, primary peritoneal, and fallopian tube cancers: A retrospective, single institute study.

  2017cited by this paper
• Safety of First-line Chemotherapy with Metronomic Single-agent Oral Vinorelbine in Elderly Patients with NSCLC.

  2017cited by this paper
• Efficacy of metronomic oral cyclophosphamide with low dose dexamethasone and celecoxib in metastatic castration‐resistant prostate cancer

  2017cited by this paper
• Outcomes of advanced epithelial ovarian cancer with integration of metronomic chemotherapy: An Indian rural cancer centre experience

  2016cited by this paper
• Metronomic cyclophosphamide therapy in hormone-naive patients with non-metastatic biochemical recurrent prostate cancer: a phase II trial

  2016cited by this paper
• Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India

  2016cited by this paper
• Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study

  2016cited by this paper
• Oral cyclophosphamide in recurrent ovarian cancer

  2016cited by this paper
• SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trial

  2016cited by this paper
• Chemotherapy in frail elderly patients with hormone-refractory prostate cancer: A “real world” experience

  2016cited by this paper
• Outcome of operable oral cavity cancer and impact of maintenance metronomic chemotherapy: A retrospective study from rural India

  2016cited by this paper
• Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature

  2016cited by this paper
• C29Metronomic oral cyclophosphamide (CTX) in patients (pts) with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC)

  2016cited by this paper
• Abstract OT3-02-04: Randomised phase II study evaluating, as first-line chemotherapy, single-agent oral vinorelbine administered with two different schedules in patients with hormone receptor positive, HER2-negative advanced breast cancer (TempoBreast-1 trial)

  2016cited by this paper
• Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients

  2016cited by this paper
• Low-Dose Oral Cyclophosphamide and Methotrexate Maintenance for Hormone Receptor-Negative Early Breast Cancer: International Breast Cancer Study Group Trial 22-00.

  2016cited by this paper
• Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.

  2015cited by this paper
• Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

  2015cited by this paper
• Continuous, low-dose capecitabine for patients with recurrent colorectal cancer

  2015cited by this paper
• On and off Metronomic Oral Vinorelbine in Elderly Women with Advanced Breast Cancer

  2015cited by this paper
• Metronomic chemotherapy with daily low-dose temozolomide and celecoxib in elderly patients with newly diagnosed glioblastoma multiforme: a retrospective analysis

  2015cited by this paper
• The results with the addition of metronomic cyclophosphamide to palliative radiotherapy for the treatment of non-small cell lung carcinoma.

  2015cited by this paper
• New Treatment Options for Patients With Metastatic Prostate Cancer: What Is The Optimal Sequence?

  2015cited by this paper
• Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib

  2015cited by this paper
• Metronomic capecitabine as extended adjuvant chemotherapy in women with triple negative breast cancer.

  2015cited by this paper
• Cisplatin in combination with metronomic vinorelbine as front-line treatment in advanced non-small cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

  2015cited by this paper
• Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple negative breast cancer: a phase III study.

  2015cited by this paper
• Metronomic oral vinorelbine as first-line treatment in elderly patients with advanced non-small cell lung cancer: results of a phase II trial (MOVE trial)

  2015cited by this paper
• Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.

  2015cited by this paper
• Metronomic chemotherapy in platinum-insensitive failures and/or early failures postmultimodality management in oral cancers

  2015cited by this paper
• Metronomic vinorelbine (oral) in combination with sorafenib in advanced non-small cell lung cancer.

  2015cited by this paper
• Phase II study of metronomic cyclophosphamide and temozolomide in platinum resistance ovarian cancer.

  2015cited by this paper
• Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration‐resistant prostate cancer patients

  2014cited by this paper
• Metronomic chemotherapy

  2014cited by this paper
• Anti-angiogenesis participates in antitumor effects of metronomic capecitabine on colon cancer.

  2014cited by this paper
• Metronomic oral cyclophosphamide plus prednisone in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer

  2014cited by this paper
• Interferon Alpha and Metronomic Cyclophosphamide for Metastatic Kidney Cancer: A Phase 2 Study

  2014cited by this paper
• Metronomic oral cyclophosphamide chemotherapy possibly contributes to stabilization of disease in patients with metastatic castration-resistant prostate cancer: a prospective analysis of consecutive cases.

  2014cited by this paper
• Metronomic oral cyclophosphamide (MOC) in the salvage therapy of heavily treated recurrent ovarian cancer patients: a retrospective, multicenter study

  2014cited by this paper
• Phase II trial of fulvestrant with metronomic capecitabine for postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.

  2014cited by this paper
• Efficacy and Safety of the All-Oral Schedule of Metronomic Vinorelbine and Capecitabine in Locally Advanced or Metastatic Breast Cancer Patients: The Phase I-II VICTOR-1 Study

  2014cited by this paper
• Preliminary results of capecitabine metronomic chemotherapy in operable triple-negative breast cancer after standard adjuvant therapy--a single-arm phase II study.

  2014cited by this paper
• The efficacy of temozolomide for recurrent glioblastoma multiforme

  2013cited by this paper
• A phase II study of metronomic oral vinorelbine administered in the second line and beyond in non-small cell lung cancer (NSCLC): a phase II study of the Hellenic Oncology Research Group

  2013cited by this paper
• Sorafenib plus daily low-dose temozolomide for relapsed glioblastoma: a phase II study.

  2013cited by this paper
• Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma.

  2013cited by this paper
• Oral metronomic scheduling of anticancer therapy-based treatment compared to existing standard of care in locally advanced oral squamous cell cancers: A matched-pair analysis.

  2013cited by this paper
• Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activity.

  2012cited by this paper
• Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial

  2012cited by this paper
• Cyclooxygenase‐2 inhibition causes antiangiogenic effects on tumor endothelial and vascular progenitor cells

  2012cited by this paper
• An all-oral combination of metronomic cyclophosphamide plus capecitabine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: a phase II study

  2012cited by this paper
• Pioglitazone, etoricoxib, interferon-α, and metronomic capecitabine for metastatic renal cell carcinoma: final results of a prospective phase II trial

  2012cited by this paper
• Metronomic oral combination chemotherapy with capecitabine and cyclophosphamide: a phase II study in patients with HER2-negative metastatic breast cancer

  2012cited by this paper
• Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.

  2012cited by this paper
• Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics

  2012cited by this paper
• Oral etoposide for platinum-resistant and recurrent epithelial ovarian cancer: a study by the Anatolian Society of Medical Oncology.

  2012cited by this paper
• Oral Metronomic Cyclophosphamide and Methotrexate Plus Fulvestrant in Advanced Breast Cancer Patients: A Mono‐Institutional Case‐Cohort Report

  2012cited by this paper
• Evaluation of oral chemotherapy with capecitabine and cyclophosphamide plus thalidomide and prednisone in prostate cancer patients

  2012cited by this paper
• Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer

  2011cited by this paper
• Sorafenib plus daily low dose temozolomide for relapsed glioblastoma: A phase II study.

  2011cited by this paper
• Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

  2011cited by this paper
• Retrospective analysis of an oral combination of dexamethasone, uracil plus tegafur and cyclophosphamide for hormone-refractory prostate cancer.

  2011cited by this paper
• Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer

  2011cited by this paper
• Phase II study of metronomic chemotherapy with bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy

  2011cited by this paper
• Effective oral combination metronomic chemotherapy with low toxicity for the management of castration-resistant prostate cancer.

  2011cited by this paper
• Metronomic (M), capecitabine (C), and oxaliplatin (O) plus bevacizumab (B) as treatment of advanced colorectal cancer (ACRC) in very elderly people (M-COB): Efficacy and safety (E&S) evaluation-A 2-year monitoring.

  2011cited by this paper
• Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.

  2011cited by this paper
• A phase 2 pilot trial of low‐dose, continuous infusion, or “metronomic” paclitaxel and oral celecoxib in patients with metastatic melanoma

  2010cited by this paper
• 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.

  2010cited by this paper
• Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma.

  2010cited by this paper
• Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

  2010cited by this paper
• Oral metronomic cyclophosphamide in elderly with metastatic melanoma

  2010cited by this paper
• Continuous low-dose temozolomide and celecoxib in recurrent glioblastoma

  2010cited by this paper
• Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy

  2010cited by this paper
• Metronomic oral cyclophosphamide prednisolone chemotherapy is an effective treatment for metastatic hormone-refractory prostate cancer after docetaxel failure.

  2010cited by this paper
• Bevacizumab plus Low-Dose Metronomic Oral Cyclophosphamide in Heavily Pretreated Patients with Recurrent Ovarian Cancer

  2010cited by this paper
• Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study.

  2010cited by this paper
• Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer.

  2010influential reference

• COVID-19 Induces Prolonged Immunological Exhaustion Leading to Relapse of Hematological Malignancies Except in Hematopoietic Cell Transplant Recipients

  2025cites this paper
• A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2‐negative metastatic breast cancer

  2023cites this paper
• A review and metanalysis of metronomic oral single-agent cyclophosphamide for treating advanced ovarian carcinoma in the era of precision medicine

  2023cites this paper
• A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy

  2023cites this paper
• Immune Targeted Therapies for COVID-19 Infection: A Narrative Review

  2022cites this paper
• Senology at the time of the coronavirus – What we did or should learn from the COVID-19 pandemic

  2021cites this paper
• Challenges posed by COVID‐19 in cancer patients: A narrative review

  2021cites this paper
• Impact of COVID-19 on Breast Cancer Treatment: A Tertiary Referral Centre Experience

  2021cites this paper
• Metronomic Chemotherapy

  2021cites this paper
• The travails of therapeutic modifications in cancer care amidst the COVID-19 pandemic: Future directions and lessons learned

  2021cites this paper
• Surgical treatment of hepatocellular carcinoma in the era of COVID-19 pandemic: A comprehensive review of current recommendations

  2021cites this paper